Literature DB >> 21366430

Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.

Anil Potti1, Sayan Mukherjee, Rebecca Petersen, Holly K Dressman, Andrea Bild, Jason Koontz, Robert Kratzke, Mark A Watson, Michael Kelley, Geoffrey S Ginsburg, Mike West, David H Harpole, Joseph R Nevins.   

Abstract

To the Editor: We would like to retract our article, "A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer,"(1) which was published in the Journal on August 10, 2006. Using a sample set from a study by the American College of Surgeons Oncology Group (ACOSOG) and a collection of samples from a study by the Cancer and Leukemia Group B (CALGB), we have tried and failed to reproduce results supporting the validation of the lung metagene model described in the article. We deeply regret the effect of this action on the work of other investigators.

Entities:  

Year:  2011        PMID: 21366430     DOI: 10.1056/NEJMc1101915

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

Review 1.  Perspectives on systems biology applications in diabetic kidney disease.

Authors:  Claudiu V Komorowsky; Frank C Brosius; Subramaniam Pennathur; Matthias Kretzler
Journal:  J Cardiovasc Transl Res       Date:  2012-06-26       Impact factor: 4.132

2.  Meet the new boss: lung cancer staging.

Authors:  Abbie Begnaud; Robert A Kratzke
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

Authors:  Fumihiro Tanaka; Kazue Yoneda
Journal:  Surg Today       Date:  2015-04-30       Impact factor: 2.549

4.  Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients.

Authors:  Ka Chen; Hongliang Liu; Zhensheng Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Qingyi Wei
Journal:  Int J Cancer       Date:  2019-02-01       Impact factor: 7.396

5.  The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.

Authors:  Chanida Vinayanuwattikun; Vinayanuwattikun Chanida; Poonchavist Chantranuwat; Chantranuwat Poonchavist; Virote Sriuranpong; Sriuranpong Virote; Apiwat Mutirangura; Mutirangura Apiwat
Journal:  Int J Clin Oncol       Date:  2013-07-04       Impact factor: 3.402

6.  How close are we to customizing chemotherapy in early non-small cell lung cancer?

Authors:  Georgios Ioannidis; Vassilis Georgoulias; John Souglakos
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

7.  Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.

Authors:  Justin M Balko; Carlos L Arteaga
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

Review 8.  Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Authors:  Bartomeu Massuti; Jose Miguel Sanchez; Florentino Hernando-Trancho; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

9.  Is there clinical value to prognostic signatures in early-stage NSCLC?

Authors:  Paul A Bunn; Fred R Hirsch; Dara L Aisner
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 10.  Prognostic and predictive biomarkers post curative intent therapy.

Authors:  Rebecca Feldman; Edward S Kim
Journal:  Ann Transl Med       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.